Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $41.20.

ELVN has been the topic of a number of research reports. Robert W. Baird increased their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, June 16th. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. Finally, The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a “buy” rating and a $37.00 price objective on the stock.

Insider Activity

In related news, CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the sale, the chief executive officer directly owned 940,392 shares of the company’s stock, valued at $21,177,627.84. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $19.79, for a total value of $131,939.93. Following the sale, the chief operating officer directly owned 296,642 shares in the company, valued at approximately $5,870,545.18. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,284 shares of company stock valued at $1,910,415. Company insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. Ameriprise Financial Inc. purchased a new position in Enliven Therapeutics during the fourth quarter worth approximately $789,000. BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics during the fourth quarter worth $112,000. Deutsche Bank AG grew its stake in shares of Enliven Therapeutics by 51.7% in the fourth quarter. Deutsche Bank AG now owns 30,516 shares of the company’s stock valued at $687,000 after buying an additional 10,397 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after buying an additional 718 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Enliven Therapeutics by 108.6% in the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company’s stock valued at $1,143,000 after purchasing an additional 26,449 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $20.01 on Wednesday. The stock has a 50-day moving average of $19.80 and a two-hundred day moving average of $19.61. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03. The stock has a market cap of $1.19 billion, a PE ratio of -10.01 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts predict that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.